Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Karin Fjordén, MD, Frida Pauly, PhD, Sirpa Leppä, MD PhD, Harald Holte, MD PhD, Magnus Björkholm, MD PhD, Oystein Fluge, MD PhD, Lars Möller Pedersen, MD PhD, Mikael Eriksson, MD PhD, Anna Isinger-Ekstrand, PhD, Carl Borrebaeck, PhD, Mats Jerkeman, MD PhD, Christer Wingren, PhD

Blood (2014) 124 (21): 1618.

https://doi.org/10.1182/blood.V124.21.1618.1618

Published: 2014

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Harald Holte, MD, PhD, Sirpa LeppÃ¤, MD, PhD, Magnus Bjorkholm, MD, PhD, Øystein Fluge, MD, PhD, Sirkku Jyrkkiö, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fosså, MD, PhD, Bj∅rn Østenstad, MD, PhD, Eva Löfvenberg, MD, Marie Nordström, MD, PhD, Lars Möller Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2010) 116 (21): 2805.

https://doi.org/10.1182/blood.V116.21.2805.2805

Published: 2010

Journal Articles

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

Satu Koivula, Minna Taskinen, Ping Chen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sampsa Hautaniemi, Sirpa Leppa

Blood (2010) 116 (21): 3107.

https://doi.org/10.1182/blood.V116.21.3107.3107

Published: 2010

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Blood (2010) 115 (8): 1530–1533.

https://doi.org/10.1182/blood-2009-08-236570

Published: 2010

Includes: Supplemental data

Journal Articles

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Harald Holte, MD, PhD, Sirpa M. Leppa, MD, PhD, Magnus Bjorkholm, MD, PhD, Oystein Fluge, MD, PhD, Sirkku Jyrkkio, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fossa, MD, PhD, Björn Östenstad, MD, PhD, Eva Lofvenberg, MD, PhD, Marie Nordström, MD, PhD, Lars Möller-Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2008) 112 (11): 3604.

https://doi.org/10.1182/blood.V112.11.3604.3604

Published: 2008

Journal Articles

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood (2008) 112 (7): 2687–2693.

https://doi.org/10.1182/blood-2008-03-147025

Published: 2008

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, Ph.D, Arne Kolstad, MD, Ph.D, Anna Laurell, MD, Ph.D, Lone B. Pedersen, B of Sc, Niels S. Andersen, MD, Ph.D, Mats Jerkeman, MD, Ph.D, Marie Nordstrom, MD, Ph.D, Grethe F. Lauritzen, MD, Ph.D, Elisabeth Ralfkiaer, MD, Ph.D, Maans Akerman, MD, Ph.D, Christer Sundstrom, MD, Ph.D, Ruth Langholm, MD, Ph.D, Marja-Liisa Karjalainen-Lindsberg, MD, Ph.D, Outti Kuittinen, MD, Ph.D, Mikael Eriksson, MD, Ph.D, Nordic Lymphoma Group

Blood (2005) 106 (11): 2429.

https://doi.org/10.1182/blood.V106.11.2429.2429

Published: 2005

Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD

Blood (2005) 106 (11): 16.

https://doi.org/10.1182/blood.V106.11.16.16

Published: 2005

NARROW

Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only